Bharat Biotech's Covaxin gets emergency approval for children aged 2-18 years

Union Minister of Health and Family Welfare, GoI, launches first commercial batch of COVAXIN manufactured in Ankleshwar, Gujarat

Bharat Biotech, today announced the commercial launch of the first batch of COVAXIN from its Chiron Behring Vaccines facility in Ankleshwar, Gujarat.

Rs 150 per dose is not sustainable in long run: Bharat Biotech on Centre's Covaxin price

Hyderabad-based vaccine maker Bharat Biotech on Tuesday said the current supply price of its Covid-19 vaccine Covaxin to the Centre is not sustainable in the long run.

Clinical trial of Bharat Biotech's Covaxin on children begins at AIIMS Patna

Manish Sisodia: Bharat Biotech says can’t give additional Covaxin doses to Delhi

Serum Institute of India reduces price of Covishield from Rs 400 to Rs 300 for states

Bharat Biotech expands its manufacturing capacity to produce 70 crore doses of Covaxin annually

Covaxin, India’s first indigenous corona vaccine, shows potency of 81 percent

<p>Indigenous Covid-19 vaccine Covaxin has demonstrated interim clinical efficacy of 81 per cent in its phase three trial. The trial involved 25 thousand 800 participants across 21 sites. The first interim analysis is based on 43 cases of which 36 cases of Covid-19 were observed in the placebo group versus 7 cases observed in the […]</p>

Covid Vaccine: government likely to buy another 4.5 crore doses of Covidshield Vaccine by April

<p>The government on Wednesday said that it is committed to buying from the Serum Institute further 4.5 crore doses of Oxford Covid-19 vaccine, Covishield, at a price of Rs 200 per shot plus applicable taxes by April, in addition to a firm order given to the company for 1.1 crore doses. From Tuesday morning onwards, […]</p>

Bharat Biotech’s Covid-19 vaccine phase-3 trials cross half-way mark of 13,000 volunteers

<p>Bharat Biotech has announced the successful recruitment of 13,000 volunteers, and continued its progress towards achieving its goal of 26,000 participants for phase-3 clinical trial across multiple sites in the country of India’s first Make in India vaccine candidate, Covaxin, against the coronavirus disease (Covid-19). The phase-3 human clinical trials of Covaxin began mid-November, targeting […]</p>